Youshibi cimzia has been approved for a variety of psoriasis in Japan

UCB, a Belgian pharmaceutical giant, recently announced that Japanese regulators have approved cimzia (Chinese trade name: siminja ®, common name: certolizumab pegol, peserizumab injection) for the treatment of plaque psoriasis, psoriasis arthritis, pustular psoriasis and erythroderma psoriasis, which are not effective in the current treatment With this approval, cimzia has become the first PEGylated anti-tumor necrosis factor - α (TNF - α) drug without Fc domain for the above patients in the Japanese market In adult patients, the approved dose of cimzia is 400mg every two weeks For maintenance dose, consider 200 mg every two weeks or 400 mg every four weeks Cimzia can be administered subcutaneously using a precharge syringe or an autoclicks ® precharge pen Cimzia was launched in Japan in March 2013 for the treatment of rheumatoid arthritis (RA) This product is produced and supplied by youshibi, exclusively distributed and sold by Astaire, and jointly promoted by youshibi Japan and Astaire In Japan, there are about 430000 psoriasis patients For this newly approved psoriasis indication, yoshibi Japan will carry out all promotion activities to expand its dermatology footprint to Japan Cimzia is the only anti TNF - α drug without Fc domain and modified by polyethylene glycol It has a very high affinity for human TNF - α and can selectively neutralize the pathophysiological role of TNF - α Because of its unique molecular structure without Fc domain, cimzia is the only anti-tumor necrosis factor (an-tnf) biological agent that has strong scientific evidence to prove that the drugs will not transfer to the fetus and infant when the women in childbearing age (from pregnancy to late pregnancy and lactation) receive treatment Up to now, cimzia has been approved by many countries and regions in the world for the treatment of a variety of inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, spinal arthritis, Crohn's disease, etc At the end of March 2019, cimzia was approved by the US FDA as a new indication for the treatment of active non radiologic axial spondyloarthroarthritis (NR axspa) in adult patients with inflammatory signs This approval makes cimzia the first drug approved by FDA to treat NR axspa.